Chemistry, physiology, and pharmacology of β-adrenergic mechanisms in the heart. Why are β-blocker antiarrhythmics superior?

abstract：:Growth factors (GFs) are extracellular signaling polypeptides regulating cell proliferation, differentiation and survival. They exert a wide spectrum of biological activities selectively binding to and activating specific membrane receptors which then transfer the message to cell interior inducing specific biochemical...

journal_title：Current pharmaceutical design

authors： D'Andrea LD,Del Gatto A,De Rosa L,Romanelli A,Pedone C

更新日期：2009-01-01 00:00:00

abstract：:Senescence is defined as an irreversible growth arrest that is characterised by a changed morphology, gene expression pattern and chromatin structure as well as an activated DNA damage response. Senescence has a dual role for tumour development-it acts as a tumour suppressor to prevent the proliferation of seriously d...

journal_title：Current pharmaceutical design

authors： Saretzki G

更新日期：2010-01-01 00:00:00

abstract：:Genetic variation in the receptors and other intracellular targets that mediate the pharmacodynamic effects of drugs can affect therapeutic outcomes. However, at present greater knowledge is available concerning the extent of gene variation in drug metabolizing enzymes that determine drug pharmacokinetics and, in turn...

journal_title：Current pharmaceutical design

authors： Crettol S,Petrovic N,Murray M

更新日期：2010-01-01 00:00:00

abstract：:α-Synuclein aggregation is centrally implicated in Parkinson's disease (PD). It involves multi-step nucleated polymerization process via the formation of dimers, soluble toxic oligomers and insoluble fibrils. In the present study, we synthesized a novel compound viz., Curcumin-glucoside (Curc-gluc), a modified form of...

journal_title：Current pharmaceutical design

authors： Gadad BS,Subramanya PK,Pullabhatla S,Shantharam IS,Rao KS

更新日期：2012-01-01 00:00:00

abstract：:Inhibition of fatty acid oxidation is well recognized as a potentially effective mechanism for controlling glycemia in non-insulin-dependent diabetes mellitus (NIDDM). However, a direct targeting of inhibition of the intramitochondrial beta-oxidation pathway or an indirect modulation of fatty acid oxidation by inhibit...

journal_title：Current pharmaceutical design

authors： Anderson RC

更新日期：1998-02-01 00:00:00

abstract：:Drug designing targeting protein-protein interactions is challenging. Because structural elucidation and computational analysis have revealed the importance of hot spot residues in stabilizing these interactions, there have been on-going efforts to develop drugs which bind the hot spots and out-compete the native prot...

journal_title：Current pharmaceutical design

authors： Ma B,Nussinov R

更新日期：2014-01-01 00:00:00

abstract：:Tamoxifen is a selective oestrogen receptor modulator (SERM). SERMs act on oestrogen receptors to inhibit oestradiol mediated negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis, thereby upregulating gonadotrophin secretion and release from the pituitary. Hence, Tamoxifen is used to upregulate activatio...

journal_title：Current pharmaceutical design

authors： Dimakopoulou A,Foran D,Jayasena CN,Minhas S

更新日期：2020-02-12 00:00:00

abstract：:Although escape from tumor dormancy has long been recognized as an important problem in the treatment of cancer, the molecular and cellular regulators underlying this transition remain poorly understood. The inability of the cancer cells to induce a complete and successful process of angiogenesis can result in tumor d...

journal_title：Current pharmaceutical design

authors： Shaked Y,McAllister S,Fainaru O,Almog N

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:Medical treatments are used either alone or in combination with assisted reproductive techniques for treatment of infertile patients with hypergonadotropic hypogonadism. A wide range of treatment options such as gonadotropins, aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs) and the...

journal_title：Current pharmaceutical design

authors： Kalkanli A,Akdere H,Cevik G,Salabas E,Cilesiz NC,Kadioglu A

更新日期：2020-11-01 00:00:00

abstract：:There is an increasing need to rapidly determine the specificity of proteases that potentially play a role in human and animal disease. Substrates for novel proteases can be discovered by testing standard protease substrates such as oxidized insulin B-chain, by screening commercially available substrates for other pro...

journal_title：Current pharmaceutical design

authors： Richardson PL

更新日期：2002-01-01 00:00:00

abstract：:Advances in particle engineering techniques, such as spray drying, freeze drying and supercritical fluid precipitation, have greatly enhanced the ability to control the structure, morphology, and solid state phase of inhalable sized particles (1 - 5 µm) for formulation in pressurized metered dose inhalers (pMDI). To o...

journal_title：Current pharmaceutical design

authors： D'Sa D,Chan HK

更新日期：2015-01-01 00:00:00

abstract：BACKGROUNDS:Targeted therapy is the foundation of personalized medicine in cancer, which is often understood as the right patient using the right drug. Thinking from the viewpoint of determinants during personalized drug treatment, the genetics, epigenetics and metagenomics would provide individual-specific biological ...

journal_title：Current pharmaceutical design

authors： Wang L,Yu X,Zhang C,Zeng T

更新日期：2018-01-01 00:00:00

abstract：:Stimulant use disorders are an unrelenting public health concern worldwide. Agonist replacement therapy is among the most effective strategies for managing substance use disorders including nicotine and opioid dependence. The present paper reviewed clinical data from human laboratory self-administration studies and cl...

journal_title：Current pharmaceutical design

authors： Stoops WW,Rush CR

更新日期：2013-01-01 00:00:00

abstract：:Carbonic anhydrases (CAs, EC 4.2.1.1) are metalloenzymes which catalyze CO(2) hydration to bicarbonate and protons. Five genetically distinct classes are known, which represent an excellent example of convergent evolution. Inhibition of α-CAs from vertebrates, including humans, with sulfonamides was exploited clinical...

journal_title：Current pharmaceutical design

authors： Supuran CT

更新日期：2010-01-01 00:00:00

abstract：:Hypertension and insomnia are very common and often coexist. There is evidence to suggest that the increasing prevalence of arterial hypertension in the past decade might be related both to an increased prevalence of insomnia and to the decline of sleep duration due to modern lifestyle. The aim of this paper is to rec...

journal_title：Current pharmaceutical design

authors： Palagini L,Bruno RM,Gemignani A,Baglioni C,Ghiadoni L,Riemann D

更新日期：2013-01-01 00:00:00

abstract：:Over the last several years, it has become increasingly clear that dendritic cells (DC) are not only critical for the initiation of T cell immunity, but these cells also determine the course of the subsequent immune response (i.e. tolerance vs. immunity, Th1 vs. Th2). However, the mechanisms by which DC can influence ...

journal_title：Current pharmaceutical design

authors： Wan Y,Bramson J

更新日期：2001-07-01 00:00:00

abstract：:Opioids remain the standard of care in the provision of analgesia in the patient undergoing cancer surgery preoperatively. The effects of opioids on tumor growth and metastasis have been discussed for many years. In recent years their use as part of the perioperative pain management bundle in the patients undergoing c...

journal_title：Current pharmaceutical design

authors： Sekandarzad MW,Doornebal C,Hollmann MW

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Radix Stephaniae Tetrandrine (RST), known as FangJi (Pinyin name) in Chinese, is the dried root of Stephania tetrandra S.Moore, and has been prescribed in combination with other herbs to treat cardiovascular diseases and breast cancer in traditional Chinese medicine (TCM) clinical trials. OBJECTIVE:The aim ...

journal_title：Current pharmaceutical design

authors： Guo Y,Chen B,Pei X,Zhang D

更新日期：2020-01-01 00:00:00

abstract：:Recent advances in DNA sequencing has made it possible to accurately decipher the entire genetic complement of a probiotic bacterium. Increases in sequencing capabilities have been enhanced through improved computer software that can annotate, or identify, the majority of genes encoded by the sequence. The availabilit...

journal_title：Current pharmaceutical design

authors： Callanan M

更新日期：2005-01-01 00:00:00

abstract：:Gonadotropin Releasing Hormone (GnRH) is at the centre of the scientific debate for the treatment of hypogonadotropic hypogonadism. Sexual maturation and reproductive function depend on the pulsatile secretion of GnRH are mainly congenital and may or may not be associated with other genetic anomalies or syndromes. Cli...

journal_title：Current pharmaceutical design

authors： Bettocchi C,Rinaldi M,Sebastiani F

更新日期：2020-11-24 00:00:00

abstract：BACKGROUND:Ximelagatran has been approved in Europe for VTE prophylaxis in orthopedic surgery at fixed doses and without laboratory monitoring. Aim of the study was to evaluate safety and efficacy of ximelagatran in a meta-analysis of prophylaxis and/or treatment randomized controlled trials. METHODS:Absolute risk of ...

journal_title：Current pharmaceutical design

authors： Iorio A,Guercini F,Ferrante F,Nenci GG

更新日期：2005-01-01 00:00:00

abstract：:The concept of probiotics has evolved immensely since it was first proposed a century ago. There are numerous potential health benefits attributed to certain probiotic bacteria, from preventing gastrointestinal (GI) infections to stimulating the immune system. Recent evidence is now quite compelling for a role of prob...

journal_title：Current pharmaceutical design

authors： O'Sullivan DJ

更新日期：2008-01-01 00:00:00

abstract：:Current antiretroviral therapy has had a significant impact on HIV associated morbidity and mortality. Despite these positive outcomes current antiretroviral regimens have significant deficiencies which include multiple drug-drug interactions, high pill burdens, and considerable financial expense. Perhaps the greatest...

journal_title：Current pharmaceutical design

authors： Romanelli F,Hoven AD

更新日期：2006-01-01 00:00:00

abstract：:Stem cell therapy heralds a new chapter in cardiovascular regenerative medicine. Cardiovascular implants are often used in both surgery and interventional cardiology. Cardiovascular stents are utilized in percutaneous coronary interventions (PCI), and are classified as either bare metal stents (BMS) or drug-eluting st...

journal_title：Current pharmaceutical design

authors： Tan A,Sumpio BE,Lee S,Seifalian AM

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Bevacizumab (BVZ) is a recombinant humanized antibody that inhibits the vascular endothelial growth factor A (VEGFA) and is used for the treatment of various types of cancer. BVZ is primarily given by the intravenous drip (I.V.), which often leads to low efficacy and various side effects. There...

journal_title：Current pharmaceutical design

authors： Jiang X,Zhang QL,Liu TG,Zhao WP,Yang M,Wang LN,Sun WL,Pan L,Luo AP,Huang JC,Gu XH

更新日期：2019-01-01 00:00:00

abstract：:Treatment of chronic lymphocytic leukemia (CLL) has recently undergone revolutionary changes. Two large randomized trials demonstrated superiority of chemoimmunotherapy combining fludarabine and cyclophosphamide with monoclonal anti-CD20 antibody rituximab (FCR) over fludarabine and cyclophosphamide (FC) alone in firs...

journal_title：Current pharmaceutical design

authors： Smolej L

更新日期：2012-01-01 00:00:00

abstract：:Approximately half of patients with schizophrenia have a lifetime diagnosis of substance abuse disorders. These dual diagnosis patients are more likely to have poorer outcomes, including more severe psychiatric symptoms with increased hospitalizations, higher utilization of services and frequent homelessness. Assessme...

journal_title：Current pharmaceutical design

authors： Tsuang J,Fong TW

更新日期：2004-01-01 00:00:00

abstract：:DNA methylation, a major regulator of epigenetic modifications has been shown to alter the expression of genes that are involved in aspects of glucose metabolism such as glucose intolerance, insulin resistance, β-cell dysfunction and other conditions, and it ultimately leads to the pathogenesis of type 2 diabetes mell...

journal_title：Current pharmaceutical design

authors： Alam F,Islam MA,Gan SH,Mohamed M,Sasongko TH

更新日期：2016-01-01 00:00:00

abstract：:In order to develop an effective pharmacological treatment for obesity, an endogenous factor that promotes a positive energy balance by increasing appetite and decreasing fat oxidation could represent the drug target scientists have been looking for. The recently discovered gastric endocrine agent ghrelin, which appea...

journal_title：Current pharmaceutical design

authors： Horvath TL,Castañeda T,Tang-Christensen M,Pagotto U,Tschöp MH

更新日期：2003-01-01 00:00:00

abstract：:Metabolic syndrome (MetS) which is caused by poor dietary habits and sedentary behavior is a serious global health problem. MetS is a cluster of risk factors, represented by central obesity, hyperglycemia, dyslipidemia, and hypertension. In the 21st century, MetS and associated comorbidities, including obesity, diabet...

journal_title：Current pharmaceutical design

authors： Korivi M,Liu BR

更新日期：2020-01-01 00:00:00